There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioMarin Pharmaceutical (BMRN) and Gilead Sciences (GILD) with bullish sentiments.
BioMarin Pharmaceutical (BMRN)
Wedbush analyst Liana Moussatos reiterated a Buy rating on BioMarin Pharmaceutical today and set a price target of $138.00. The company’s shares closed last Wednesday at $74.49.
According to TipRanks.com, Moussatos is a 5-star analyst with an average return of 10.4% and a 47.0% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Global Blood Therapeutics, and Eiger Biopharmaceuticals.
BioMarin Pharmaceutical has an analyst consensus of Moderate Buy, with a price target consensus of $111.35.
See today’s analyst top recommended stocks >>
Gilead Sciences (GILD)
According to TipRanks.com, Singh is a 4-star analyst with an average return of 9.1% and a 44.4% success rate. Singh covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Alexion Pharmaceuticals, and Vertex Pharmaceuticals.
Currently, the analyst consensus on Gilead Sciences is a Moderate Buy with an average price target of $79.06.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GILD:
